Department of Dermatology, Taikang Tongji (Wuhan) Hospital, Wuhan, China.
J Clin Lab Anal. 2022 Feb;36(2):e24198. doi: 10.1002/jcla.24198. Epub 2021 Dec 24.
MicroRNA (miR)-146a and miR-146b regulate autoimmunity, inflammation, and keratinocytes proliferation to engage in psoriasis pathology. The current study aimed to investigate their correlation with disease risk and clinical features, and the linkage of their longitudinal changes with clinical response to etanercept in psoriasis patients.
Plasma samples were collected from 84 moderate-to-severe psoriasis patients who underwent etanercept treatment (at baseline (M0), 1 month (M1), 3 months (M3), and 6 months (M6)), 80 disease controls and 80 health controls (both after enrollment); afterward, miR-146a and miR-146b expressions were detected by RT-qPCR. Furthermore, PASI75 and PASI90 responses were assessed in psoriasis patients.
Both miR-146a and miR-146b were decreased in psoriasis patients compared with disease controls and health controls (all p < 0.001), which also distinguished psoriasis patients from disease controls and health controls by receiver-operating characteristic analyses. Furthermore, miR-146a positively correlated with miR-146b in psoriasis patients (p < 0.001) and disease controls (p = 0.005) but not in healthy controls (p = 0.062). In psoriasis patients, miR-146a negatively related to psoriatic body surface area (p = 0.011) and PASI score (p = 0.003); miR-146b negatively linked with PASI score (p = 0.020). At M1, M3, and M6 after etanercept treatment, PASI75 response rate was 14.3%, 32.1%, and 69.0%, respectively; PASI90 response rate was 1.2%, 17.9%, and 36.9%, respectively. During etanercept treatment, both miR-146a and miR-146b elevated gradually over time and their longitude increments were associated with PASI75 response (all p < 0.001).
MiR-146a and miR-146b might serve as indicators for optimizing etanercept application and improving treatment outcomes in psoriasis patients.
微小 RNA（miR）-146a 和 miR-146b 调节自身免疫、炎症和角质形成细胞增殖，从而参与银屑病发病机制。本研究旨在探讨它们与疾病风险和临床特征的相关性，以及它们的纵向变化与银屑病患者接受依那西普治疗后的临床反应之间的联系。
采集 84 例中重度银屑病患者（在基线（M0）、1 个月（M1）、3 个月（M3）和 6 个月（M6）时接受依那西普治疗）、80 例疾病对照者和 80 例健康对照者的血浆样本；采用 RT-qPCR 检测 miR-146a 和 miR-146b 的表达情况。此外，评估银屑病患者的 PASI75 和 PASI90 应答情况。
与疾病对照者和健康对照者相比，银屑病患者的 miR-146a 和 miR-146b 均降低（均 p<0.001），且通过受试者工作特征分析可将银屑病患者与疾病对照者和健康对照者区分开来。此外，miR-146a 与 miR-146b 在银屑病患者（p<0.001）和疾病对照者（p=0.005）中呈正相关，但在健康对照者中无相关性（p=0.062）。在银屑病患者中，miR-146a 与银屑病体表面积（p=0.011）和 PASI 评分（p=0.003）呈负相关；miR-146b 与 PASI 评分（p=0.020）呈负相关。依那西普治疗 1 个月（M1）、3 个月（M3）和 6 个月（M6）后，PASI75 应答率分别为 14.3%、32.1%和 69.0%；PASI90 应答率分别为 1.2%、17.9%和 36.9%。在依那西普治疗期间，miR-146a 和 miR-146b 随时间逐渐升高，其纵向增加与 PASI75 应答相关（均 p<0.001）。
miR-146a 和 miR-146b 可作为优化依那西普应用和改善银屑病患者治疗效果的指标。
